Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 15 December 2000:
Vol. 290. no. 5499, pp. 2049 - 2051
DOI: 10.1126/science.290.5499.2049b
Prev | Table of Contents | Next

News of the Week

GENE THERAPY:
FDA Moves Against Penn Scientist

Gretchen Vogel

The U.S. Food and Drug Administration (FDA) has begun proceedings that could disqualify gene therapy researcher James Wilson of the University of Pennsylvania in Philadelphia from conducting any future clinical trials. Wilson, who is head of the university's Institute for Human Gene Therapy, oversaw the trial in which 18-year-old Jesse Gelsinger died after a genetically altered virus was injected into his liver. Disqualification is the harshest penalty the FDA can impose on an investigator.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)